Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Janssen Japan Chief Calls for Appropriate Rewards for Innovative Drugs
May 29, 2018
- Perspective on Takeda/Shire Deal - 1: Profits Delivered by On-Market Products More Important than Pipeline
May 29, 2018
- Pfizer Submits New Drug Application in Japan for Dacomitinib
May 29, 2018
- MSD Launches Prevymis for Prevention of CMV Infection
May 29, 2018
- JCR to Start PII Study of Hunter Syndrome Treatment in Brazil in June
May 29, 2018
- European Regulator Accepts Mitsubishi Tanabe’s Edaravone Filing for ALS
May 29, 2018
- Takeda Sales Reps Heavily Pitch Inisync, Takecab in February: Anterio Ranking
May 28, 2018
- FDA Extends Action Date for Lenvima’s HCC Indication by 3 Months
May 28, 2018
- AbbVie Seeks Japan Approval for Psoriasis Drug Risankizumab
May 28, 2018
- Opdivo/Yervoy Combo Gains Japan Nod for Melanoma
May 28, 2018
- 3 Generic Major Companies Maintain Double-Digit Growth in FY2017: Jiho Tally
May 28, 2018
- Otsuka/Lundbeck to Launch Add’l PIII for Brexpiprazole in June
May 25, 2018
- Chugai Seeks Still’s Disease Indication for Actemra
May 25, 2018
- Maviret Top Seller Drug in Japan in January-March: IQVIA
May 23, 2018
- Astellas Eyes 1 Trillion Yen Peak Sales with 6 Late-Stage Assets: Biz Plan
May 23, 2018
- Astellas to Shed 600 Jobs to Revamp Japan Operations
May 23, 2018
- Hemlibra, MSD/Astellas’ DPP-4/SGLT2 Combo Hit Japan Market
May 23, 2018
- Top 4 Wholesalers Report Unusually Low Growth in Drug Wholesale Business for 2nd Year after Price Revision
May 23, 2018
- JCR’s Sakigake-Designated Hunter Syndrome Treatment to Enter PII/III in 1st Half of FY2018
May 23, 2018
- Janssen Files Triple-Combo for HIV Treatment in Japan
May 23, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…